The recent report by Togni et al. (1) presents the results of a study that evaluated the coronary vasomotor response after sirolimuseluting stent (SES) implantation. The investigators concluded that implantation of SES is associated with endothelial dysfunction in proximal and distal regions of treated coronary segment, whereas in the control group, bare-metal stents did not affect physiologic response to exercise.
Life-Threatening Coronary Artery Spasm Following Sirolimus-Eluting Stent Deployment
We were interested to read the report by Togni et al. (1) , with its accompanying editorial (2), on paradoxical coronary vasoconstriction associated with sirolimus-eluting stents (SESs). We would like to report a case of life-threatening coronary artery spasm following drug-eluting stent deployment. A 55-year-old man was recently treated in our department after presenting with recurrent ischemic symptoms. He first presented with angina in August 2003, when a proximal stenosis of the right coronary artery was treated with a paclitaxel-eluting stent (Conor Medsystems, Menlo Park, California) as part of a clinical trial. He developed further exertional angina in May 2004, when angiography revealed restenosis of the right coronary artery stent. This was treated by cutting balloon dilation followed by intracoronary brachytherapy with a 60-mm beta-emitting source (BetaCath, Novoste, Norcross, Georgia).
In November 2004 he presented with unstable angina when coronary angiography confirmed recurrent restenosis at the proximal and distal edges of the original stent. This was treated by the direct deployment of SESs (Cypher Select, Cordis Europa NV, Amersfoort, the Netherlands), overlapping the existing stent proximally and distally. Four hours after stent deployment, the patient developed chest discomfort associated with ventricular fibrillation. After successful defibrillation, he returned immediately to the catheterization laboratory, where repeat angiography showed the right coronary artery to be patent (Fig. 1) . Within minutes of this diagnostic image, however, the patient developed further chest pain associated with ST-segment elevation in the inferior leads. Prompt repeat angiography at this stage confirmed occlusive spasm of the right coronary artery distal to the SES (Fig. 2) . This improved following intracoronary nitrate administration (Fig. 3) . As we believed the severe spasm in this region to be the cause of the earlier ventricular fibrillation, we elected to deploy a paclitaxeleluting stent (Taxus Express, Boston Scientific, Marlborough, Massachusetts) to cover the vasospastic arterial segment (Fig. 4 ). An excellent angiographic result was achieved, and the patient has remained asymptomatic at follow-up.
This case illustrates that occlusive coronary spasm may develop after drug-eluting stent deployment with potentially life-threatening consequences. We can only speculate whether the abnormal vasomotion in the arterial segment distal to the SES was attributable to a local effect of sirolimus on endothelial function (3), or to late endothelial dysfunction following brachytherapy (4). The history of prior treatment of the vessel with paclitaxel may also be relevant. Nonetheless, the potential for drug-eluting stents to unfavorably alter coronary vasomotion is worthy of further study. 
REPLY
Regarding our recent study in JACC (1), we would like to thank Drs. Kipshidze and Leon for the clarifying arguments on the effects of sirolimus and paclitaxel on endothelial cells. We agree that endothelial dysfunction and incomplete vascular healing may play a key role in the development of peristent lesions and late stent thrombosis after drug-eluting stent (DES) implantation, although this link has not been established so far. We can only support the need for inclusion of functional studies before introduction of new DESs in order to identify potential negative effects on endothelial recovery and vascular healing. 
